Indegene Limited raises ₹ 548.77 crore from 36 anchor investors at the upper price band of ₹452 per equity share - Indegene Limited raises ₹548.77 crore from 36 anchor investors at the upper price band of ₹452 per equity share - CtrlS Noida Datacenter Turns to Solar for 60% of its Power Requirement, Aims to reduce 94,640 tonnes of CO2 emissions through this move - TBO TEK LIMITED ANNOUNCED IT'S INITIAL PUBLIC OFFERING (IPO) TO OPENS ON 08th May, 2024 Sets Price Band fixed at ₹ 875 to ₹ 920 per equity share of face value of ₹ 1 each - Afternoon Voice Hosts 16th Newsmakers Achievers Award 2024, Recognising Outstanding Contributions Across Various Fields - AADHAR HOUSING FINANCE LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) OF EQUITY SHARES OPENS ON MAY 8, 2024 Sets Price Band fixed at ₹ 300 to ₹ 315 per equity share of face value of ₹ 10 each - Sankalp Art Fest Presents An Art Exhibition will be held @ Namah Royal Banquet Hall at Borivali (W) in Mumbai - Collaborates with the Akshaya Patra Foundation for Sustainable Growth in India - Kokilaben Hospital launches Arthrex Modular Glenoid System with VIP for Enhanced Shoulder Replacement for the First Time in India - उत्तर मुंबई मतदार संघातील पीयूष गोयल यांचा उमेदवारी अर्ज दाखल, जल्लोषात समर्थन देत भाजप - महायुती कार्यकर्त्यांचे जोरदार शक्तीप्रदर्शन

Woman Triumphs Over Lymphoma With CAR T Cell Therapy

She’s the first person in Andhra Pradesh to have successfully treated with indigenously built therapy

Navi Mumbai, 5 April 2024 (GNI) Despite being diagnosed with refractory diffuse large B-Cell lymphoma (DLBCL), 47-year-old Ms Reddi Lalitha Kumari from Bobbili town in Vizianagaram district of Andhra Pradesh, never took a day off from work in 24 years.

However, this dedicated high school Mathematics teacher’s journey was fraught with challenges– a testament to the complexity of refractory DLBCL. Refractory disease means the patient’s disease stopped responding to all the conventional treatment options that are available. In Ms Lalitha’s case, her cancer staged a fierce comeback, defying all standard therapies.

But her will to fight against the disease and her dream to see their twin daughters settle down in their lives, motivated Ms Lalitha to undergo CAR T Cell Therapy at Apollo Cancer Centre, Visakhapatnam.

The team led by Dr. Rakesh Reddy BoyaSenior Consultant – Medical & Hemato OncologyDr. Ventrapati PradeepConsultant – Medical Oncology, and Dr. G Veni PrasannaConsultant – Pathologist, explored advanced treatment options. According to Dr Boya, Ms. Lalitha’s case required a different approach due to the refractory nature of the disease and CAR-T Cell Therapy emerged as a viable option, offering a chance to be “cancer free.”

Dr. Rakesh Reddy Boya, Senior Consultant – Medical & Hemato Oncology, Apollo Cancer Centre, Vizag, said, “Following Ms Lalitha’s initial response to R-CHOP therapy, her relapse posed a formidable challenge. Through strategic intervention and the integration of salvage chemotherapy, including R-ICE, we achieved a remarkable complete response. It was through meticulous analysis, collaboration, and unwavering determination that we charted a path towards her recovery. This victory reinforces our commitment to pushing the boundaries of cancer care and providing hope to those in need.”

Following the CAR-T Cell therapy, Ms. Lalitha’s cancer led to a complete remission. “The most incredible news was hearing from the doctors – I am cancer-free. Being a maths teacher, I always believe that every problem has a solution and in my case, I got the right treatment at Apollo Cancer Centre,” she smiles. “This treatment has given me a second lease of life, and I’m incredibly grateful to the team at ACC for their expertise and unfaltering support.” ends GNI

Be the first to comment on "Woman Triumphs Over Lymphoma With CAR T Cell Therapy"

Leave a comment

Your email address will not be published.


*